Locoregional administration of 5-fluoro-2′-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1991-07

AUTHORS

B. Naser-Hijazi, M. R. Berger, D. Schmähl, P. Schlag, W. E. Hull

ABSTRACT

The influence of infusion time and dose on the anticancer efficacy of 5-fluoro-2′-deoxyuridine (FdUrd) was investigated using a locoregional therapy model: Novikoff hepatoma transplanted i.m. into the thigh of Wistar rats and FdUrd infusion via a catheter implanted in the femoral artery. In experiment A the FdUrd dose (five daily doses of 12, 19 and 30 mg/kg) and the duration of administration (bolus, 1 h, 5 h, and 24 h) were varied. The change in tumor volume following treatment and the number of rats showing regression vs progression served as indicators of therapy response. The results showed a clear dose dependence, and for each infusion time the 30 mg/kg dose was the most effective, without any signs of general toxicity. At this dose the longest infusion time (24 h) was less effective (regression in three of six rats) compared with 1-h or 5-h treatments (four of five in regression). In experiment B either one or five daily FdUrd doses (15, 30, 60 mg/kg) were administered i.a. for the same infusion times used in experiment A. After treatment, tumors were explanted ex vivo and approximately 1-g tissues samples were immediately frozen in liquid nitrogen for storage.19F-NMR spectroscopy at 11.7 T was used to quantify FdUrd metabolites [5-fluorouracil (FUra),α-fluoro-β-alanine (FβAla.), 5-fluorouracil nucleosides and nucleotides (F-Nuc)] in the solid tumor tissue samples (maintained at 4° C) with a detection threshold of about 5 nmol/g. The metabolite signal pattern indicated that FdUrd is first converted to FUra, followed by anabolism primarily to nucleotides in the oxy form (e.g. FUTP). The total amount of fluorine detected in tumor tissue increased with dose and decreased with infusion time. For all treatments FNuc could be detected, even after 24 h infusion, and their levels showed a good linear correlation with the total F. The major catabolite FβAla was present in tumor at low levels that correlated poorly with total F, indicating recirculation from other organs (e.g. liver) as the main source. Thus, the NMR method can provide detailed information regarding the efficiency of locoregional treatment (catheter function, drug uptake and metabolism). Initial results of non-invasive in vivo NMR experiments are also presented. More... »

PAGES

295-304

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01630711

DOI

http://dx.doi.org/10.1007/bf01630711

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005974419

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1829730


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Floxuridine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intra-Arterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms, Experimental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Spectroscopy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Inbred Strains", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naser-Hijazi", 
        "givenName": "B.", 
        "id": "sg:person.01267001054.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267001054.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berger", 
        "givenName": "M. R.", 
        "id": "sg:person.01256203524.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256203524.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schm\u00e4hl", 
        "givenName": "D.", 
        "id": "sg:person.0105462430.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0105462430.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, University Clinic, W-6900, Heidelberg, Federal Republic of Germany", 
          "id": "http://www.grid.ac/institutes/grid.411544.1", 
          "name": [
            "Department of Surgery, University Clinic, W-6900, Heidelberg, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schlag", 
        "givenName": "P.", 
        "id": "sg:person.01074415550.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074415550.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Central Spectroscopy Department, German Cancer Research Center, W-6900, Heidelberg, Federal Republic of Germany", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Central Spectroscopy Department, German Cancer Research Center, W-6900, Heidelberg, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hull", 
        "givenName": "W. E.", 
        "id": "sg:person.0656770604.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656770604.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1989.275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041875826", 
          "https://doi.org/10.1038/bjc.1989.275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00402774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003074278", 
          "https://doi.org/10.1007/bf00402774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-82635-1_22", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010935838", 
          "https://doi.org/10.1007/978-3-642-82635-1_22"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00391597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013765337", 
          "https://doi.org/10.1007/bf00391597"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00389963", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002871991", 
          "https://doi.org/10.1007/bf00389963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-82635-1_19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017224414", 
          "https://doi.org/10.1007/978-3-642-82635-1_19"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-07", 
    "datePublishedReg": "1991-07-01", 
    "description": "The influence of infusion time and dose on the anticancer efficacy of 5-fluoro-2\u2032-deoxyuridine (FdUrd) was investigated using a locoregional therapy model: Novikoff hepatoma transplanted i.m. into the thigh of Wistar rats and FdUrd infusion via a catheter implanted in the femoral artery. In experiment A the FdUrd dose (five daily doses of 12, 19 and 30 mg/kg) and the duration of administration (bolus, 1 h, 5 h, and 24 h) were varied. The change in tumor volume following treatment and the number of rats showing regression vs progression served as indicators of therapy response. The results showed a clear dose dependence, and for each infusion time the 30 mg/kg dose was the most effective, without any signs of general toxicity. At this dose the longest infusion time (24 h) was less effective (regression in three of six rats) compared with 1-h or 5-h treatments (four of five in regression). In experiment B either one or five daily FdUrd doses (15, 30, 60 mg/kg) were administered i.a. for the same infusion times used in experiment A. After treatment, tumors were explanted ex vivo and approximately 1-g tissues samples were immediately frozen in liquid nitrogen for storage.19F-NMR spectroscopy at 11.7 T was used to quantify FdUrd metabolites [5-fluorouracil (FUra),\u03b1-fluoro-\u03b2-alanine (F\u03b2Ala.), 5-fluorouracil nucleosides and nucleotides (F-Nuc)] in the solid tumor tissue samples (maintained at 4\u00b0 C) with a detection threshold of about 5 nmol/g. The metabolite signal pattern indicated that FdUrd is first converted to FUra, followed by anabolism primarily to nucleotides in the oxy form (e.g. FUTP). The total amount of fluorine detected in tumor tissue increased with dose and decreased with infusion time. For all treatments FNuc could be detected, even after 24 h infusion, and their levels showed a good linear correlation with the total F. The major catabolite F\u03b2Ala was present in tumor at low levels that correlated poorly with total F, indicating recirculation from other organs (e.g. liver) as the main source. Thus, the NMR method can provide detailed information regarding the efficiency of locoregional treatment (catheter function, drug uptake and metabolism). Initial results of non-invasive in vivo NMR experiments are also presented.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf01630711", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "117"
      }
    ], 
    "keywords": [
      "infusion time", 
      "tumor tissue", 
      "duration of administration", 
      "tissue samples", 
      "clear dose dependence", 
      "tumor tissue samples", 
      "number of rats", 
      "effect of dose", 
      "longer infusion time", 
      "locoregional treatment", 
      "femoral artery", 
      "h infusion", 
      "Wistar rats", 
      "tumor volume", 
      "therapy response", 
      "locoregional administration", 
      "tumor growth", 
      "dose", 
      "rats", 
      "metabolite levels", 
      "experiment A.", 
      "general toxicity", 
      "anticancer efficacy", 
      "treatment", 
      "infusion", 
      "tumors", 
      "administration", 
      "therapy model", 
      "Novikoff hepatoma", 
      "experiment A", 
      "experiment B", 
      "tissue", 
      "low levels", 
      "dose dependence", 
      "artery", 
      "catheter", 
      "levels", 
      "thigh", 
      "doses", 
      "FUra", 
      "progression", 
      "solid tumor tissue samples", 
      "efficacy", 
      "hepatoma", 
      "FdUrd", 
      "vivo", 
      "organs", 
      "detection threshold", 
      "signs", 
      "toxicity", 
      "anabolism", 
      "duration", 
      "metabolites", 
      "linear correlation", 
      "signal patterns", 
      "total amount", 
      "regression", 
      "initial results", 
      "time", 
      "response", 
      "samples", 
      "vivo NMR experiments", 
      "A.", 
      "detailed information", 
      "Novikoff", 
      "correlation", 
      "effect", 
      "volume", 
      "changes", 
      "results", 
      "threshold", 
      "indicators", 
      "main source", 
      "liquid nitrogen", 
      "patterns", 
      "nucleotides", 
      "good linear correlation", 
      "number", 
      "growth", 
      "information", 
      "amount", 
      "form", 
      "by19F NMR spectroscopy", 
      "recirculation", 
      "method", 
      "influence", 
      "model", 
      "source", 
      "experiments", 
      "oxy form", 
      "storage", 
      "dependence", 
      "nitrogen", 
      "efficiency", 
      "spectroscopy", 
      "fluorine", 
      "NMR experiments", 
      "NMR methods"
    ], 
    "name": "Locoregional administration of 5-fluoro-2\u2032-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by19F-NMR spectroscopy", 
    "pagination": "295-304", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005974419"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01630711"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1829730"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01630711", 
      "https://app.dimensions.ai/details/publication/pub.1005974419"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_246.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf01630711"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01630711'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01630711'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01630711'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01630711'


 

This table displays all metadata directly associated to this object as RDF triples.

260 TRIPLES      21 PREDICATES      141 URIs      127 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01630711 schema:about N0635afbc3aba46d48c739530a03deb98
2 N0655184c374b41e9a4d3b4727f1bd245
3 N344e3792e8d3489a835076d9da2c6281
4 N49f8a118667c47eab24445f21f58f82e
5 N62b8da59d5144e72b059c9ec42f92868
6 N7d5d62a17f1445aa8727ddf911818457
7 Nac6952b00d4440d88ef1e104a4b9a515
8 Nad59c957b821415689ced21bb74de03c
9 Nae29e020f98a416f84d695dd65192029
10 Nd8788fc3ac954cae9354d834ef5d04ac
11 Nefe55ba340ed4c48b49a0f8144775609
12 anzsrc-for:11
13 anzsrc-for:1115
14 schema:author Ned6e3b715a284015a78f1cba4bb2a906
15 schema:citation sg:pub.10.1007/978-3-642-82635-1_19
16 sg:pub.10.1007/978-3-642-82635-1_22
17 sg:pub.10.1007/bf00389963
18 sg:pub.10.1007/bf00391597
19 sg:pub.10.1007/bf00402774
20 sg:pub.10.1038/bjc.1989.275
21 schema:datePublished 1991-07
22 schema:datePublishedReg 1991-07-01
23 schema:description The influence of infusion time and dose on the anticancer efficacy of 5-fluoro-2′-deoxyuridine (FdUrd) was investigated using a locoregional therapy model: Novikoff hepatoma transplanted i.m. into the thigh of Wistar rats and FdUrd infusion via a catheter implanted in the femoral artery. In experiment A the FdUrd dose (five daily doses of 12, 19 and 30 mg/kg) and the duration of administration (bolus, 1 h, 5 h, and 24 h) were varied. The change in tumor volume following treatment and the number of rats showing regression vs progression served as indicators of therapy response. The results showed a clear dose dependence, and for each infusion time the 30 mg/kg dose was the most effective, without any signs of general toxicity. At this dose the longest infusion time (24 h) was less effective (regression in three of six rats) compared with 1-h or 5-h treatments (four of five in regression). In experiment B either one or five daily FdUrd doses (15, 30, 60 mg/kg) were administered i.a. for the same infusion times used in experiment A. After treatment, tumors were explanted ex vivo and approximately 1-g tissues samples were immediately frozen in liquid nitrogen for storage.19F-NMR spectroscopy at 11.7 T was used to quantify FdUrd metabolites [5-fluorouracil (FUra),α-fluoro-β-alanine (FβAla.), 5-fluorouracil nucleosides and nucleotides (F-Nuc)] in the solid tumor tissue samples (maintained at 4° C) with a detection threshold of about 5 nmol/g. The metabolite signal pattern indicated that FdUrd is first converted to FUra, followed by anabolism primarily to nucleotides in the oxy form (e.g. FUTP). The total amount of fluorine detected in tumor tissue increased with dose and decreased with infusion time. For all treatments FNuc could be detected, even after 24 h infusion, and their levels showed a good linear correlation with the total F. The major catabolite FβAla was present in tumor at low levels that correlated poorly with total F, indicating recirculation from other organs (e.g. liver) as the main source. Thus, the NMR method can provide detailed information regarding the efficiency of locoregional treatment (catheter function, drug uptake and metabolism). Initial results of non-invasive in vivo NMR experiments are also presented.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N04acba00e28a4abb9833d9c927fe9e88
27 N188c3942b10843b2908e72e4fdf4331d
28 sg:journal.1313647
29 schema:keywords A.
30 FUra
31 FdUrd
32 NMR experiments
33 NMR methods
34 Novikoff
35 Novikoff hepatoma
36 Wistar rats
37 administration
38 amount
39 anabolism
40 anticancer efficacy
41 artery
42 by19F NMR spectroscopy
43 catheter
44 changes
45 clear dose dependence
46 correlation
47 dependence
48 detailed information
49 detection threshold
50 dose
51 dose dependence
52 doses
53 duration
54 duration of administration
55 effect
56 effect of dose
57 efficacy
58 efficiency
59 experiment A
60 experiment A.
61 experiment B
62 experiments
63 femoral artery
64 fluorine
65 form
66 general toxicity
67 good linear correlation
68 growth
69 h infusion
70 hepatoma
71 indicators
72 influence
73 information
74 infusion
75 infusion time
76 initial results
77 levels
78 linear correlation
79 liquid nitrogen
80 locoregional administration
81 locoregional treatment
82 longer infusion time
83 low levels
84 main source
85 metabolite levels
86 metabolites
87 method
88 model
89 nitrogen
90 nucleotides
91 number
92 number of rats
93 organs
94 oxy form
95 patterns
96 progression
97 rats
98 recirculation
99 regression
100 response
101 results
102 samples
103 signal patterns
104 signs
105 solid tumor tissue samples
106 source
107 spectroscopy
108 storage
109 therapy model
110 therapy response
111 thigh
112 threshold
113 time
114 tissue
115 tissue samples
116 total amount
117 toxicity
118 treatment
119 tumor growth
120 tumor tissue
121 tumor tissue samples
122 tumor volume
123 tumors
124 vivo
125 vivo NMR experiments
126 volume
127 schema:name Locoregional administration of 5-fluoro-2′-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by19F-NMR spectroscopy
128 schema:pagination 295-304
129 schema:productId N3a1a2c1c235249ea9ec8cf326aee5f4b
130 N6bf644ecec3246769a9b5433bb6bf37f
131 Nb3f18ead3d734afeb2e22dfcfb1b2044
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005974419
133 https://doi.org/10.1007/bf01630711
134 schema:sdDatePublished 2022-12-01T06:20
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher Nf8f28fb06dcd45e29a92a608818fdd70
137 schema:url https://doi.org/10.1007/bf01630711
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N04acba00e28a4abb9833d9c927fe9e88 schema:issueNumber 4
142 rdf:type schema:PublicationIssue
143 N0635afbc3aba46d48c739530a03deb98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 N0655184c374b41e9a4d3b4727f1bd245 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Drug Administration Schedule
148 rdf:type schema:DefinedTerm
149 N13f990a9e37148b0ae273c76cc28ed1b rdf:first sg:person.01256203524.22
150 rdf:rest Ncab666c2d2bf45e9b6362f0fd5adda32
151 N188c3942b10843b2908e72e4fdf4331d schema:volumeNumber 117
152 rdf:type schema:PublicationVolume
153 N344e3792e8d3489a835076d9da2c6281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Floxuridine
155 rdf:type schema:DefinedTerm
156 N3a1a2c1c235249ea9ec8cf326aee5f4b schema:name dimensions_id
157 schema:value pub.1005974419
158 rdf:type schema:PropertyValue
159 N49f8a118667c47eab24445f21f58f82e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Neoplasm Transplantation
161 rdf:type schema:DefinedTerm
162 N515783794fc340f08b2158258d41f304 rdf:first sg:person.0656770604.03
163 rdf:rest rdf:nil
164 N62b8da59d5144e72b059c9ec42f92868 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Infusions, Intra-Arterial
166 rdf:type schema:DefinedTerm
167 N6bf644ecec3246769a9b5433bb6bf37f schema:name doi
168 schema:value 10.1007/bf01630711
169 rdf:type schema:PropertyValue
170 N7d5d62a17f1445aa8727ddf911818457 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Animals
172 rdf:type schema:DefinedTerm
173 Nac6952b00d4440d88ef1e104a4b9a515 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Liver Neoplasms, Experimental
175 rdf:type schema:DefinedTerm
176 Nad59c957b821415689ced21bb74de03c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Magnetic Resonance Spectroscopy
178 rdf:type schema:DefinedTerm
179 Nae29e020f98a416f84d695dd65192029 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Rats
181 rdf:type schema:DefinedTerm
182 Nb3f18ead3d734afeb2e22dfcfb1b2044 schema:name pubmed_id
183 schema:value 1829730
184 rdf:type schema:PropertyValue
185 Ncab666c2d2bf45e9b6362f0fd5adda32 rdf:first sg:person.0105462430.55
186 rdf:rest Ndfdfbeecb91c485583e85156730fd9bb
187 Nd8788fc3ac954cae9354d834ef5d04ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Rats, Inbred Strains
189 rdf:type schema:DefinedTerm
190 Ndfdfbeecb91c485583e85156730fd9bb rdf:first sg:person.01074415550.10
191 rdf:rest N515783794fc340f08b2158258d41f304
192 Ned6e3b715a284015a78f1cba4bb2a906 rdf:first sg:person.01267001054.57
193 rdf:rest N13f990a9e37148b0ae273c76cc28ed1b
194 Nefe55ba340ed4c48b49a0f8144775609 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Fluorine
196 rdf:type schema:DefinedTerm
197 Nf8f28fb06dcd45e29a92a608818fdd70 schema:name Springer Nature - SN SciGraph project
198 rdf:type schema:Organization
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
203 schema:name Pharmacology and Pharmaceutical Sciences
204 rdf:type schema:DefinedTerm
205 sg:journal.1313647 schema:issn 0171-5216
206 1432-1335
207 schema:name Journal of Cancer Research and Clinical Oncology
208 schema:publisher Springer Nature
209 rdf:type schema:Periodical
210 sg:person.0105462430.55 schema:affiliation grid-institutes:grid.7497.d
211 schema:familyName Schmähl
212 schema:givenName D.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0105462430.55
214 rdf:type schema:Person
215 sg:person.01074415550.10 schema:affiliation grid-institutes:grid.411544.1
216 schema:familyName Schlag
217 schema:givenName P.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074415550.10
219 rdf:type schema:Person
220 sg:person.01256203524.22 schema:affiliation grid-institutes:grid.7497.d
221 schema:familyName Berger
222 schema:givenName M. R.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256203524.22
224 rdf:type schema:Person
225 sg:person.01267001054.57 schema:affiliation grid-institutes:grid.7497.d
226 schema:familyName Naser-Hijazi
227 schema:givenName B.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267001054.57
229 rdf:type schema:Person
230 sg:person.0656770604.03 schema:affiliation grid-institutes:grid.7497.d
231 schema:familyName Hull
232 schema:givenName W. E.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656770604.03
234 rdf:type schema:Person
235 sg:pub.10.1007/978-3-642-82635-1_19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017224414
236 https://doi.org/10.1007/978-3-642-82635-1_19
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/978-3-642-82635-1_22 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010935838
239 https://doi.org/10.1007/978-3-642-82635-1_22
240 rdf:type schema:CreativeWork
241 sg:pub.10.1007/bf00389963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002871991
242 https://doi.org/10.1007/bf00389963
243 rdf:type schema:CreativeWork
244 sg:pub.10.1007/bf00391597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013765337
245 https://doi.org/10.1007/bf00391597
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/bf00402774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003074278
248 https://doi.org/10.1007/bf00402774
249 rdf:type schema:CreativeWork
250 sg:pub.10.1038/bjc.1989.275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041875826
251 https://doi.org/10.1038/bjc.1989.275
252 rdf:type schema:CreativeWork
253 grid-institutes:grid.411544.1 schema:alternateName Department of Surgery, University Clinic, W-6900, Heidelberg, Federal Republic of Germany
254 schema:name Department of Surgery, University Clinic, W-6900, Heidelberg, Federal Republic of Germany
255 rdf:type schema:Organization
256 grid-institutes:grid.7497.d schema:alternateName Central Spectroscopy Department, German Cancer Research Center, W-6900, Heidelberg, Federal Republic of Germany
257 Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG
258 schema:name Central Spectroscopy Department, German Cancer Research Center, W-6900, Heidelberg, Federal Republic of Germany
259 Institute of Toxicology and Chemotherapy, DKFZ, Im Neuenheimer Feld 280, W-6900, Heidelberg, FRG
260 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...